Antithrombin concentrate use in children: a multicenter cohort study
- PMID: 23932317
- PMCID: PMC3812320
- DOI: 10.1016/j.jpeds.2013.06.036
Antithrombin concentrate use in children: a multicenter cohort study
Abstract
Objective: To describe the off-label use of antithrombin concentrate in tertiary care pediatric hospitals across the US.
Study design: This is a retrospective, multicenter, cohort study of 4210 admissions of children younger than 18 years of age who received antithrombin concentrate between 2002 and 2011 within the Pediatric Health Information System administrative database. An on-label admission was defined as an admission with an International Classification of Diseases diagnostic code for a primary hypercoagulable state; admissions without this code were classified as off-label.
Results: During the 10-year study period, off-label use of antithrombin concentrate increased 5-fold. Overall, 97% of study subjects received antithrombin off-label. Neonates younger than 30 days of age comprised the largest age group (45.7%) of use; 87% of patients had at least one complex chronic condition, with congenital heart/lung defects being the most prevalent primary diagnosis (36.3%). Extracorporeal membrane oxygenation was the most common procedure associated with antithrombin use (43.7%).
Conclusions: The off-label use of antithrombin concentrate is increasing rapidly, particularly in critically ill children receiving extracorporeal membrane oxygenation, with few parallel studies to substantiate its safety or efficacy. Further preclinical and controlled clinical studies are critical to expanding our knowledge of this drug. In the meantime, antithrombin concentrate should be used judiciously by clinicians and following guidelines instated by hospitals.
Keywords: CCC; CPB; Cardiopulmonary bypass; Complex chronic conditions; ECMO; Extracorporeal membrane oxygenation; FDA; Food and Drug Administration; ICD-9-CM; International Classification of Diseases, 9thRevision, Clinical Modification; PHIS; Pediatric Health Information System.
Copyright © 2013 Mosby, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Antithrombin Concentrate Use in Pediatric Extracorporeal Membrane Oxygenation: A Multicenter Cohort Study.Pediatr Crit Care Med. 2016 Dec;17(12):1170-1178. doi: 10.1097/PCC.0000000000000955. Pediatr Crit Care Med. 2016. PMID: 27662567
-
Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study.Pediatr Crit Care Med. 2015 Mar;16(3):264-9. doi: 10.1097/PCC.0000000000000322. Pediatr Crit Care Med. 2015. PMID: 25581634
-
Antithrombin use during pediatric cardiac extracorporeal membrane oxygenation admission: insights from a national database.Perfusion. 2021 Mar;36(2):138-145. doi: 10.1177/0267659120939758. Epub 2020 Jul 10. Perfusion. 2021. PMID: 32650697
-
A narrative review of antithrombin use during veno-venous extracorporeal membrane oxygenation in adults: rationale, current use, effects on anticoagulation, and outcomes.Perfusion. 2020 Sep;35(6):452-464. doi: 10.1177/0267659120913803. Epub 2020 Mar 31. Perfusion. 2020. PMID: 32228213 Review.
-
Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate.Transfus Med Rev. 2016 Oct;30(4):189-96. doi: 10.1016/j.tmrv.2016.07.002. Epub 2016 Jul 25. Transfus Med Rev. 2016. PMID: 27576087 Review.
Cited by
-
Antithrombin III Doses Rounded to Available Vial Sizes in Critically Ill Pediatric Patients.J Pediatr Pharmacol Ther. 2017 Jan-Feb;22(1):15-21. doi: 10.5863/1551-6776-22.1.15. J Pediatr Pharmacol Ther. 2017. PMID: 28337077 Free PMC article.
-
Impact of inflammation and steroids on anti-coagulation in children supported on a ventricular assist device.J Artif Organs. 2024 Dec;27(4):368-374. doi: 10.1007/s10047-024-01442-2. Epub 2024 Apr 6. J Artif Organs. 2024. PMID: 38581568
-
Hemostasis in neonatal ECMO.Front Pediatr. 2022 Aug 26;10:988681. doi: 10.3389/fped.2022.988681. eCollection 2022. Front Pediatr. 2022. PMID: 36090551 Free PMC article. Review.
-
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO.Crit Care. 2020 Jan 20;24(1):19. doi: 10.1186/s13054-020-2726-9. Crit Care. 2020. PMID: 31959232 Free PMC article. Review.
-
Anticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current Issues.Front Pediatr. 2016 Jun 22;4:67. doi: 10.3389/fped.2016.00067. eCollection 2016. Front Pediatr. 2016. PMID: 27446890 Free PMC article. Review.
References
-
- Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thrombosis and haemostasis. 2009 May;101(5):806–812. - PubMed
-
- Franzen LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. The Journal of biological chemistry. 1980 Jun 10;255(11):5090–5093. - PubMed
-
- Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998 Jun 15;91(12):4561–4571. - PubMed
-
- Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. The Journal of biological chemistry. 1992 Jun 25;267(18):12528–12538. - PubMed
-
- Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994 May;87(1):106–112. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources